SCHEMBL876587

SCHEMBL876587

CCN(Cc1ccc(Cl)nc1)/C(=C/N(O)O)NC

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 2/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
FAAH O00519 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
CHRNA1 P02708 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA7 P36544 1/20 0.33
CHRNA4 P43681 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13040227 0.88 ALDH1A1 (0.38) ALDH1A1KDM4EGAAMAPTL3MBTL1
SCHEMBL14646127 0.82 MEN1 (0.35) ALDH1A1KDM4EGAAMAPTL3MBTL1
SCHEMBL13822120 0.82 ALDH1A1 (0.37) ALDH1A1KDM4EGAAMAPTL3MBTL1
Nitenpyram SCHEMBL25789 0.81 SMN1; SMN2 (0.40) ALDH1A1MAPTFAAHCHRNA1CHRNB2
Nitenpyram SCHEMBL29388004 0.81 SMN1; SMN2 (0.40) ALDH1A1MAPTFAAHCHRNA1CHRNB2
Nitenpyram SCHEMBL13448342 0.81 SMN1; SMN2 (0.40) ALDH1A1MAPTFAAHCHRNA1CHRNB2
Nitenpyram SCHEMBL25788 0.81 SMN1; SMN2 (0.40) ALDH1A1MAPTFAAHCHRNA1CHRNB2
Nitenpyram SCHEMBL31030931 0.81 SMN1; SMN2 (0.40) ALDH1A1MAPTFAAHCHRNA1CHRNB2
Nitenpyram SCHEMBL28400760 0.79 SMN1; SMN2 (0.39) ALDH1A1MAPTFAAHNPC1RAB9A
SCHEMBL8401753 0.79 MAPT (0.43) ALDH1A1KDM4EGAAMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143192-B2 Methods for increasing the resistance of plants to hypoxic conditions BAYER CROPSCIENCE N.V. (BE) 2012-03-27 US disclosed
WO-2012017971-A1 PEST CONTROL COMPOSITION 住友化学株式会社 (JP) 2012-02-09 WO disclosed
US-20100291022-A1 Fly Gel Bait BAYER CROPSCIENCE AG (DE) 2010-11-18 US disclosed
US-20090270254-A1 Increase of stress tolerance by application of neonicotinoids on plants engineered to be stress tolerant BAYER CROPSCIENCE AG (DE) 2009-10-29 US disclosed
US-20090064371-A1 Methods for Increasing the Resistance of Plants to Hypoxic Conditions BAYER BIOSCIENCE N.V. (BE) 2009-03-05 US disclosed
US-20080261810-A1 Insecticides Based on Neonicotinoids and Safeners BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2008-10-23 US disclosed
US-20080089857-A1 Fly Gel Bait BAYER CROPSICIENCE LP (US) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261810-A1 Insecticides Based on Neonicotinoids and Safeners CYP4X1, PRDX4, PRDX1 ALDH1A1 3269/4885KDM4E 4060/4885GAA 2711/4885
US-20100291022-A1 Fly Gel Bait MSN, WAPL, ARFGEF1 ALDH1A1 4705/4885KDM4E 2669/4885GAA 4108/4885
US-20080089857-A1 Fly Gel Bait MSN, WAPL, ARFGEF1 ALDH1A1 4748/4885KDM4E 2661/4885GAA 4203/4885
US-20090270254-A1 Increase of stress tolerance by application of neonicotinoids on plants engineered to be stress tolerant CDA, NAPRT, NIT2 ALDH1A1 664/4885KDM4E 3262/4885GAA 1181/4885
US-20090064371-A1 Methods for Increasing the Resistance of Plants to Hypoxic Conditions COXFA4L2, HIF1A, HYOU1 ALDH1A1 1125/4885KDM4E 1812/4885GAA 1978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.